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Introduction
The primary goal of my studies has been to understand how PH domain recognition of phospholipids and of other proteins contributes to signaling by the wide array of molecules that contain PH domains -the 11 th most common domain in the human genome, and one that is present in many proteins implicated in breast cancer (Cesareni et al, 2004; Schmidt and Hall, 2002) . Elucidation of the nature of these PH domain interactions (and how they are regulated) in sufficient detail may suggest approaches for inhibiting these interactions pharmacologically. This report will enumerate the advances I have made towards reaching these goals. In addition to the proposed in vitro phospholipid binding studies and in vivo cellular localization studies, I have also characterized a specific PH domain-alkylphospholipid drug interaction in vitro, and have completed the structural determination of a member of a poorly characterized class of PH domains bound to phospholipid. At least two members of this class of PH domains (FAPP2 and OSBP2) have been associated with breast cancer development or progression (Fournier et al, 1999; Scanlan et al, 2001) .
Following the format of my proposed Statement of Work, my progress towards this aim is summarized as follows:
Task 1
Investigate affinity and specificity of phosphoinositide binding to isolated human PH domains I have analyzed the phosphoinositide binding specificity of 21 of the 66 phylogenetic representative human PH domains proposed for study with lipid overlay assays (dot blot) and SPR lipid-binding assays, as previously described (Kavran et al, 1998; Yu et al, 2004 ). An extensive literature search confirmed that another 8 PH domains that have already bee characterized for phosphoinositide binding in vitro (Yu et al, 2006; Rajala et al, 2005; Yan et al, 2005; Skowronek et al, 2004; Saxena et al, 2002; Dowler et al, 2000; Fleming et al, 2000) . As expected from our prior analysis of yeast PH domains, the majority of the human PH domains selected bind phosphoinositides promiscuously and with only low affinity (compare Tables 1 &  2) . Six of the human PH domains tested possessed high affinity and specificity for phosphoinositides (either for PtdIns(4,5)P 2 , PtdIns(3,4,5)P 3 , or PtdIns(3,4)P 2 /PtdIns(3,4,5)P 3 ; see Figure 1 ), and only one yeast PH domain. The two human PH domains of OSBP1 and FAPP1 represent a separate group of domains that are promiscuous in their phosphoinositide binding, yet have moderate-to-high affinity for these phospholipids when assessed using surface plasmon resonance studies. The corresponding yeast orthologs of mammalian OSBP are Osh1p and Osh2p (Lehto et al, 2001; Yu et al, 2004) .
The OSBP/FAPP/Osh PH domain family has been at times both poorly characterized and mischaracterized in vivo and in vitro. Several of these PH domains were initially identified as PtdIns4P-specific in vitro, and, since that time, have been consistently misused as markers of cellular PtdIns4P in vivo (Várnai and Balla, 1998; Dowler et al, 2000) . In contrast to reported PtdIns4P specificity, I have determined that the PH domains of OSBP1 and FAPP1 display in vitro binding affinities that are comparable between PtdIns(4)P (K d 3.5 and 21 μM, respectively) and PtdIns(4,5)P 2 (K d 3.3 and 17 μM, respectively), as measured by SPR lipid-binding assays (Figure 2) . These results are consistent with those reported for the fusion PH domain constructs in an earlier study (Levine & Munro, 2002) . When the assay was expanded to include other phosphoinositides (clear area of Table 4 ), OSBP1 was found to have comparable in vitro binding affinities for all phosphoinositides tested (Kd 3.2-3.8 μΜ), except for the two-fold weaker affinity of PtdIns3P (apparent Kd 6.5 μΜ) and no binding for PtdIns5P. These data mirror published in vitro binding affinities of the yeast ortholog Osh1p PH, and sharply contrast with the high affinity and PtdIns(4,5)P 2 specificity of PLCδ PH (shaded area of Table 4 ). Interestingly, FAPP1 PH appears to have an intermediate specificity for phosphoinositides; in addition to the comparable binding affinities for PtdIns(4)P and PtdIns(4,5)P 2 (K d 21 and 17 μM, respectively), it has a two-fold weaker affinity for PtdIns(3,5)P 2 (K d 31.4 μM), but displays no binding for other phosphoinositides. The implications of these data will be discussed later.
Another outcome of these studies was the identification of a human PH domain with unexpected phosphoinositide-binding properties. As shown in Figure 3 , the PH domain of SH3BP-2 (3BP-2) is highly specific for PI(3,4)P 2 , but with only moderate affinity, unlike other high affinity, 3-phosphoinositide binding PH domains (like Akt1/PKBα PH). The K d is 0.3-0.5 μM for the dimeric GST-PH fusion construct (and an estimated ten-fold weaker for monomer (Kavran et al, 1998) ). SH3BP-2 is an adaptor protein with a versatile role in a variety of cell types (Figure) . It is in the same phylogenetic PH domain class as that of DAPP1 PH (a PtdIns(3,4)P 2 /PtdIns(3,4,5)P 3 -specific, high affinity PH domain), and, like DAPP1 PH, is translocated to the plasma membrane upon PI3K activation (http://www.signaling-gateway.org/). These results are consistent with the protein's PI3K-dependent roles as a positive regulator of IL-2 gene induction in T cells (Deckert et al, 1998) , NK cell-mediated cytotoxicity (Jevremovic et al, 2001) , and FcεRI-induced degranulation and signal amplification in mast cells (Sada et al, 2002) .
Task 2
Determine the subcellular localization of the PH domains.
Since PH domains are most commonly thought of as membrane-targeting modules (a function of their phospholipid binding), one might expect that PH domains with high, but not low, affinities for phosphoinositides should be membrane-localized in vivo. I strongly suspected this would not be true universally for all human PH domains, as several low affinity PH domains showed a surprising degree of localization to various cellular membranes in a previous yeast genomewide study (Yu et al, 2004) . In my original proposal, I proposed an in vivo fluorescence localization study of the representative human GFP-PH domain fusion constructs. By 2005, the Alliance for Cell Signaling (AfCS) laboratory at Stanford had completed an comparable study of mouse PH domain localization in two separate mouse cell lines (72 in WEHI-231 cells and 148 in RAW 264.7 cells) (http://www.signaling-gateway.org/). This study provided in vivo localization data covering 45 of the 66 human PH domains phylogenetic classes listed in our original proposal (including 18 of the 21 PH domains that I had tested for phosphoinositide binding)( Tables 2 & 3) . Therefore, I elected not to reproduce the in vivo studies already completed by the AfCS study. The overall distribution of cytosolic versus membrane-or punctalocalized PH domains is comparable to that of our yeast PH domain study. Furthermore, as with the yeast study, several human PH domains with low affinities for phosphoinositides in vitro unpredictably demonstrated plasma membrane or punctate localization in vivo.
In order to determine the cellular localization of OSBP1 PH and FAPP1 PH in vivo, I transfected GFP fusion constructs into live NIH-3T3 and HeLa cells. The fluorescence localization in these cells was punctate in nature (Figure 4) , consistent with Golgi membrane localization, as found in previous studies (Levine & Munro, 2002; Godi et al, 2004; Balla et al, 2005) . The in vivo data is also consistent with the reported roles of this class of PH domains in coordinating budding and fission events at the Golgi for the generation of cargo transporters targeted for fusion with the plasma membrane (Itoh & De Camilli, 2004; Roth 2004) . The data are seemingly at odds, however, with the aforementioned in vitro data demonstrating the promiscuity (and relatively weak affinity, in the case of FAPP1 PH) for phosphoinositides. Specifically, the observation that OSBP/FAPP/Osh1 PH family members target to the PtdIns4Prich Golgi rather than the PtdIns(4,5)P 2 -rich plasma membrane in vivo, despite no apparent difference in in vitro binding affinities for their respective phosphoinositide, is unexpected. This is the subject of the subsequent task.
Task 3 Screen for putative interacting proteins of PH domains
Since phosphoinositide binding alone cannot account for the specific subcellular localization of several PH domains -particularly in the case of the OSBP/FAPP/Osh1 PH family -it has been suggested that other targets, particularly proteins, may help define their localization. Levine and Munro observed that Golgi targeting of the OSBP1 PH domain requires both PtdIns4P and a second PI4K-independent determinant, which they suggested from genetic studies might be Arf1, a Golgi small GTPase (Levine & Munro, 2002) . More recently, the PH domains of both OSBP1 and FAPP1 were found to specifically and directly interact with Arf1 in vitro (Godi et al, 2004) .
I have utilized purified myristoylated Arf1 (DNA construct provided by Paul Randazzo (Manser & Leung, 2002) ) to test its reported interaction with GST-tagged FAPP1 PH and OSBP PH using GST-pulldown assays (similar to the one published in Godi et al, 2004) . Results confirm what appears to be a relatively weak and non-robust interaction in vitro (Figure 5) . Although the PH domain literature is replete with instances of in vitro pulldowns of putative protein partners, there are inherent limitations in relying on this approach to prove direct, biologically significant PH domain-protein interactions in vivo. My previously stated goal was to quantitatively measure the binding affinity of this putative PH domain-Arf1 interaction.
There appears to be some consensus that both Arf1 and PtdIns4P are both necessary to provide a sufficiently strong interaction with the PH domains in vivo (Itoh & De Camilli, 2004; Godi et al, 2004; Levine & Munro, 2002) . The challenge is to present both the myristoylated Arf1 and PtdIns(4)P in sufficient proximity to one another to allow simultaneous interactions with the PH domains, and to maintain a cellular membrane-like structure that would convincingly demonstrate the likelihood of such an interaction occurring in vivo. To accomplish this task, I plan to generate combined myrArf1/phosphoinositide (PtdIns4P:PC) vesicles to quantitatively measure the binding affinity of the interaction using SPR assays. I have found one instance in the literature where myrArf1 was successfully incorporated into lipid vesicles, and plan to broadly follow its protocol (Randazzo 1997) . This project is still in progress.
Task 4: Structure Determination of Osh1p PH domains
One of the primary motivations of this study is to structurally characterize PH domainphosphoinositide ligand interactions in detail. In addition to the seeming disconnect between in vitro binding affinity data and in vivo cellular localization data (which may be at least partly explained by the existence of the Golgi-based protein partner Arf1), a basic issue concerning the similar in vitro binding affinities between PtdIns(4)P and PtdIns(4,5)P 2 for Osh1p/OSBP/FAPP1 PH still remains unanswered. All previously published PH domain structures (liganded or liganded) interact with two adjascent ligand determinants (whether the 3-P and the 4-P of DAPP1 PH/Ins(1,3,4,5)P4 complex, the 4-P and the 5-P of PLCδ PH/Ins(1,4,5)P3 complex, or simply two free phosphate groups of unliganded DAPP1 PH (DiNitto et al, 2003) ). As phosphate groups on the inositol head group are the major PH domain determinants, how (and why) would a PH domain recognize a monophosphoinositide and diphosphoinositide with similar binding affinities? What are the structural determinants that account for PH domain promiscuity? I am addressing this question using two approaches.
Upon performing a gel filtration assay, I observed that while some [ 3 H]-Ins(1,4,5)P 3 (PtdIns(4,5)P 2 headgroup) coeluted with GST-PLCδ PH, no [ 3 H]-Ins(1,4,5)P 3 was detected coeluting with the GST-PH domains of Osh1p, OSBP, or FAPP1 (data not shown). These results suggest that the Osh1p/OSBP/FAPP1 PH domain family bind Ins(1,4,5)P 3 weakly (<1 μM, the approximate detection limit of this assay) or not at all. To distinguish between these possibilities and further identify whether the determinants are the glycerol moiety or nearby acyl chains of the phosphoinositide, I performed SPR lipid competition studies, preincubating inositol headgroups / phosphoinositides of different lengths with the OSBP PH before applying it to lipid (3% PtdIns(4)P and PtdIns(4,5)P 2 in PC background) surfaces (Figure 6A) . I also tested InsP 6 , (which unexpectedly coeluted with the PH domains in the gel filtration assay), and Ins(1,3,4,5,6)P 5 as a control (to determine whether InsP 6 binding is InsP 6 -specific or nonspecific due to high negative charge density (Shears 2002) ). The results (Figure 6B) were consistent with gel filtration data: 1) Ins(1,4,5)P 3 did not compete OSBP PH off PtdIns(4)P or PtdIns(4,5)P 2 surfaces, suggesting headgroup contacts alone are weak relative to the entire phosphoinositide; 2) both InsP 6 and Ins(1,3,4,5,6)P 5 effectively competed OSBP PH off PtdIns(4)P and PtdIns(4,5)P 2 surfaces, suggesting the importance of nonspecific electrostatic interactions; 3) all inositol phosphates and phosphoinositides (except C4-PtdIns(4)P) competed PLCδ PH off PtdIns(4,5)P 2 surface as expected, since PLCδ PH strongly interacts with headgroup (Note: PLCδ PH does not interact with PtdIns(4)P surface). Additionally, 4) short-chain phosphoinositides C4-PtdIns(4)P and C4-PtdIns(4,5)P 2 did noticeably compete OSBP PH off PtdIns(4)P and PtdIns(4,5)P 2 surfaces, suggesting a rather modest contribution from the glycerol moiety and/or acyl side chains. The data suggest that membrane surface interactions and/or insertion into the membrane may contribute quite substantially to the promiscuity observed in the Osh1p/OSBP/FAPP1 PH domain family.
To identify the specific contribution of the ligand determinants to PH domain binding, I proposed to determine the structure of the PH domain complexed with phosphoinositides. I have prepared crystals of monomeric His-tagged Osh1 PH complexed with the soluble, short chain (C4) derivatives of both PtdIns(4)P and PtdIns(4,5)P 2 (Figure 7A) . I have collected a full structure data set of the PtdIns(4,5)P 2 -and PtdIns(4)P-complexed Osh1 crystals on-site, and have identified a molecular replacement solution working with DAPP1 PH. While I am still in the process of obtaining higher resolution data, some interesting details are emerging. The phosphate "footprints" in the Osh1 PH/PtdIns(4,5)P 2 electron density map are not in the position that one would expect for two adjascent phosphates, but rather two non-adjascent ones, a result never observed for PH domains up to now (Figure 7B) . Additionally, there is only one prominent phosphate "footprint" in the Osh1 PH/PtdIns(4)P electron density map. In both instances, the phosphoinositide (and the critical β1-β2 loop) are positioned further outside the Osh1 PH lipid binding site then that observed for other PH-PPIns complexes, an observation that explains why the Osh1p/OSBP/FAPP family of PH domains bind more weaky and promiscuously to phosphoinositides then members the high affinity and specific PH domain class (eg.-PLCδ PH; see Table 4 ). Interactions with other phosphoinositide determinants (phosphate or acyl chain) await a higher resolution structure, to be completed by next month.
PH domains as drug targets in cancer therapy
Our original view of PH domains suggested that phosphoinositide-binding PH domains themselves should make poor targets for pharmacological intervention, since most phosphoinositide-recognition events are essentially the same, and, moreover, drugs likely to target PH domains are very highly charged, which leads to delivery problems. Recently, I was presented with a unique opportunity to test the PH domain-binding properties of perifosine, a C 18 -alkylphospholipid drug that has completed phase I trials (Van Ummersen et al, 2004; Crul et al, 2004) as an anti-cancer agent. Earlier immunoprecipitation studies suggested that perifosine specifically inhibits Ser/Thr phosphorylation and kinase activation of Akt1/PKBα in vivo and in vitro (Kondapaka et al, 2003) . Myristoylated Akt1/PKBα, which is targeted directly to the plasma membrane in a PH domain-independent manner, is unaffected by perifosine treatment. It was therefore hypothesized that perifosine might act by directly interfering with the phosphoinositide binding (or other membrane-targeting interaction) of the Akt1/PKBα PH domain. I have recently completed a series of SPR binding studies suggesting that perifosine specifically competes with phosphoinositides for binding to the PH domain of Akt1/PKBα (EC 50 26 μM), while it competes substantially less for binding to the PH domain of PLCδ, and not at all for the PH domains of DAPP1 (Figure 8 ) and FAPP1 (data not shown). These studies indicate that perifosine may bind directly to the phosphoinositide-binding site of the Akt1/PKBα PH domain.
Key Research Accomplishments
• GST-PH domain fusion constructs (21 of the 66 representative PH domains) have been tested for their phosphoinositide affinity and specificity in vitro by dot blot and SPR(BIAcore) assays. The overall distribution of high, moderate, and low affinity PH domains in the human proteome appears to be comparable with that of yeast. • GFP-PH domain fusion constructs of several moderate affinity and promiscuous PH domains were tested for in vivo localization in MDA-MB-468 and NIH 3T3 cells, demonstrating punctate localization. • The binding affinities of monomeric OSBP1 PH and FAPP1 PH for all phosphoinositides using SPR assays were tested demonstrating the promiscuity of OSBP1 PH and, to a lesser extent, FAPP1. • Differences between phosphoinositide binding in vitro between OSBP1 PH and PLCδ PH were observed in gel filtration and SPR competition studies, suggesting that the inositol head group or nearby acyl chains cannot fully account for the full extent of PH domain-phospholipid surface interaction of this class of PH domains. • Weak myrArf1 interactions with OSBP PH and FAPP1 PH were demonstrated in vitro using GST pulldown assays . • Completed structure determination using molecular replacement solution for Osh1p PH in complex with both PtdIns4P and PtdIns(4,5)P 2 . • A unique PH domain (SH3BP-2) with moderate affinity, yet high specificity for PI(3,4)P 2 has been characterized. • An alkylphospholipid drug has been identified as highly specific for the PH domain of Akt1/PKBα to the exclusion of several other related PH domains by SPR competition assays, despite its relatively weak affinity as determined by ITC.
Reportable Outcomes
• Publications include contributing authorship in peer-reviewed journal (Yu et al, 2004) , book chapter review of PH domains (Cesarini et al (ed.), 2004) , and review article (in press). • Abstracts and posters for Era of Hope Meeting and Annual Departmental Retreats.
• GST-and GFP-PH domain fusion constructs for many of the representative PH domains that had been originally proposed have been cloned. • Complete phylogenetic tree (dendrogram) of the entire human and yeast PH domain proteome.
• Complete phylogenetic tree (dendrogram) of other protein-binding domains of the human proteome including PTB, EVH/WH1, and RanBD. • Molecular coordinate model for Osh1p PH complexed with both PtdIns4P and PtdIns(4,5)P 2 at 2Å resolution.
Conclusion
The key question underlying all of my research accomplishments to date is: How do nonspecific and specific component interactions cooperate to drive selective membrane targeting? I have demonstrated that membrane targeting by the PH domain requires multipoint contacts, which may include both protein-protein and protein-lipid interactions (Figure 9) . In the case of OSBP1 and FAPP1 (Figure 9A ), it appears that the PH domain must simultaneously interact with both Arf1 and phosphoinositide to target to the Golgi (although I have not yet quantifted this interaction). In the case of SH3BP-2 (Figure 9B) , the SH2 and PR domains both cooperate with the PtdIns(3,4)P 2 -specific PH domain (which I have characterized) to drive plasma membrane targeting upon receptor activation. In both instances, these relatively weak affinity, high specificity protein-protein interactions are supplemented by of moderate affinity protein-phosphoinositide interactions.
I have also demonstrated that, with regard to phosphoinositide recognition of PH domains, not all phosphoinositide interactions among PH domains are equivalent. I have described a class of PH domains which bind monophosphoinositides and diphosphoinositides with comparable affinity in vitro, although they target to specifically to the Golgi in vivo (Figure  9C) . At least part of this promiscuity can be explained by membrane surface interactions or insertion of the PH domain. The structural model I have at this stage suggests a unique arrangement of PH domain interactions with nonadjascent phosphates on the phosphoinositide, an observation that is unique among PH domain structures defined to date. Additionally, I have characterized an alkylphospholipid drug (perifosine) which appears to have high specificity, but low affinity, for Akt1/PKBα PH, a PH domain with high affinity and specificity for the 3'phosphoinositides PtdIns(3,4)P 2 .and PtdIns(3,4,5)P 3 (Figure 9D) . Table 1 Yeast PH Domains Num1p Cla4p
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KIAA0053, RhoGAP25 Myosin X-Nt Yeast PH domain affinity in vitro and localization in vivo Color: High affinity and PI(4,5)P 2 -specific in red, High affinity and PI(3,4)P 2 /PI(3,4,5)P 3 -specific in green, Moderate affinity and promiscuous in purple, Low affinity and promiscuous in blue. Font: Cytosolic and nuclear localization is regular, Plasma membrane localization is bold, Punctate localization is italicized (see Yu et al, 2004 for details).
Table 2
Human PH domain affinity in vitro and localization in vivo See above for color and font key (Sources for affinity and localization include Kavran et al, 1998; Ferguson et al, 2000; Snyder et al, 2001, and unpublished data) . Localization data from mouse was used (See WEHI-231 and RAW 264.7 Image Data in http://www.signaling-gateway.org for details). * While not on the list of 66 representative PH domains, the PH domains of OSBP1 and FAPP1 are related to FAPP2. In particular, the PH domains of FAPP1 and FAPP2 have similar phosphoinositide-and Arf1-binding properties in vivo and in vitro (Godi et al, 2004) . SPR binding assay protocol detailed in Yu et al, 2004 . BIAcore response is based on refractive index changes that accompany protein binding to a lipid-coated chip surface (PtdIns(4,5)P 2 , PtdIns(3,4)P 2 , PtdIns4P). The apparent Kd is calculated from repeated iterations of Y=(Rmax*((1/Kd)*X)/(1+((1/Kd)*X)))+cf, where Rmax is the maximal response and cf is the correction factor. BIAcore response is based on refractive index changes that accompany protein binding to a lipid-coated chip surface. The apparent Kd is calculated from repeated iterations of Y=(Rmax*((1/Kd)*X)/(1+((1/Kd)*X)))+cf, where Rmax is the maximal response and cf is the correction factor. GST pulldown data suggest weak myrArf1 interactions with OSBP and FAPP1 PH.
Recombinant myristoylated Arf1 was expressed and purified as previously described (Cesareni et al, 2004) . GST-OSBP-PH and GST-FAPP1-PH were expressed and purified as previous GST-tagged proteins, with the exception that they were retained immobilized, and not eluted, on the glutathione-Sepharose beads (Lemmon et al, 1995; Yu et al, 2004) . myrArf1 was loaded with 100 μM GTP-γS or GDP by a 1 hr incubation at 32 0 C in HEPES loading buffer, followed by a 1 hr. incubation with GST-PH domain immobilized on glutathione-Sepharose beads at RT, as described previously (Godi et al, 2004) . Beads were collected by low-speed centrifugation, washes 3X, and resuspended in 3X sample buffer. Sample was boiled for 5 min at 95 0 C, and run on a 15% SDS-PAGE. Proteins were transferred to nitrocellulose paper by Western blot, blocked for 10 min in Blotto buffer with 5% dry milk, and incubated with A) mouse anti-GST antibody (1:1000, QIAgen), or B) goat anti-Arf1 antibody (1:1000, Santa Cruz Biotech) in 1X PBS O/N at 4 0 C. The blot was washed 3X with 1X PBS, followed by a 1 hr incubation at 4 0 C with secondary antibody (rabbit anti-mouse (Amersham) and donkey anti-goat (Santa Cruz Biotech), respectively), and washed again 3X. Finally, the blot was developed with ECL reagents, as per the manufacturer's (Amersham) instructions.
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